Amol Akhade: Tislelizumab gets FDA approval for Metastatic GE junction adenocarcinoma based upon rationale 305 trial
Amol Akhade, Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, posted on X:
“Tislelizumab gets FDA approval for Metastatic Gastric or GE junction adenocarcinoma Her2 negative with PDL1 More than 1 %. This is based upon rationale 305 trial. One more option of IO in this space where pembrolizumab and nivo are already approved irrespective of PDL1.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023